Hemogenyx Pharmaceuticals

Dear Friends! We would like to thank you All for your hard work and dedication in the departing 2020. Together we have further developed Hemogenyx Pharmaceuticals positioning it to become a clinical-stage company in the coming 2021.... Our hard work is reflected in the interest of a dramatically larger number of investors and translated into the share price of HEMO. We have provided an outstanding return on investment to our shareholders increasing the value of the company by more than 490% in 2020. Given numerous reported developments that include Penn's collaboration and the recent fundraising initiative, We have no doubt that the next year will be transformational. It goes without saying that, as it had been from the very first day of Hemogenyx Pharmaceuticals, our sights are laser-focused on our ultimate goal - saving the lives of patients. That is why Hemogenyx Pharmaceuticals is a Life Saving Company. We wish you and all you love a Happy and Prosperous New Year! www.hemogenyx.com

Watch our (Hemogenyx Pharmaceuticals) #HEMO presentation at #ASH2020 conference. "FLT3-CD3 Bispecific Antibody Specifically Eliminates Normal Hematopoietic Progenitors and AML in Humanized Mouse Models" #AML https://youtu.be/A7ROU8npL40

Hemogenyx Pharmaceuticals is looking for a Research Associate. We are hiring!

A new video explaining Financing Facility is on our youtube channel, a short trading update https://youtu.be/-q9FyVXSTOs

Our first small publication is out at ASH/Blood FLT3-CD3 Bispecific Antibody Specifically Eliminates Normal Hematopoietic Progenitors and AML in Humanized Mouse Models Clinical proof of concept is to follow. https://ashpublications.org//FLT3-CD3-Bispecific-Antibody-